Heart Disease is Down, Gout is Up, Biosimilars Confuse Patients and more from EULAR 2017
EULAR 2017 wraps on Saturday. In this slideshow, we highlight some of the most popular presentations from the meeting.
Adalimumab Biosimilar Performs Well in RA Trial
The biosimilar adalimumab-atto is equivalent to its reference product — which it slightly outperformed in this trial.
RA Patients Respond Well to Biosimilar in Phase III Trial
Research Roundup: Vaccine Efficacy in Rheumatoid Arthritis
Vaccine efficacy in RA, biosimilar safety and the danger of steroid injections for knee osteoarthritis top this week's research roundup. In this slideshow, we feature these and other recent research findings from the key journals.
Biosimilar Proves to be OK for Switching
Clinical trial shows that switching from the infliximab originator to its biosimilar does not compromise safety or effectiveness of treatment.
FDA Approves Biosimilar to Etanercept
Etanercept-szzs (Erelzi, Sandoz) has been approved by the U.S. Food and Drug Administration for RA and more.
Lessons from the “Biosimilarized”
A new report confirms that discounts for biosimilars do not determine global uptake and prescription incentives to encourage the use of biosimilars are hit and miss.
FDA Committee Recommends Two Biosimilars
Biosimilars to Humira and Enbrel are one step closer to the marketplace with FDA advisory committee approval.
Biosimilar Confidence: Patient Perspectives on a New Medication Class
Global Healthy Living Foundation and CreakyJoints president and co-founder, Seth Ginsberg, cautions against extrapolation, but is optimistic about biosimilars.
Biosimilar Switching Not for All Remicade Patients
ARD study recommends against biosimilar switching for patients positive for anti-infliximab (Remicade) antibodies.